PMID- 35295159 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220319 IS - 2673-3080 (Electronic) IS - 2673-3080 (Linking) VI - 3 DP - 2021 TI - Impact of Quantisal((R)) Oral Fluid Collection Device on Drug Stability. PG - 670656 LID - 10.3389/ftox.2021.670656 [doi] LID - 670656 AB - The stability of drugs can affect drug tests and interpretations. A comprehensive study to verify drug stability in Quantisal((R)) oral fluid (OF) collection device was undertaken in accordance with Australian standard, AS/NZS 4760:2019 (SAI-Global, 2019). The evaluation was performed for the following drugs: (+/-) amphetamine, (+/-) methylamphetamine, (+/-) 3,4-methylenedioxymethylamphetamine (MDMA), (-)Delta9-tetrahydrocannabinol (THC), cocaine, benzoylecgonine, morphine, codeine, and oxycodone. Stability was assessed at four different storage temperatures over seven time points at +/-50% cut-off concentrations (Appendix A, Para A4-4.1, AS/NZS 4760:2019) (SAI-Global, 2019). All drugs were found to be significantly more stable at 4 and -20 degrees C, with stability spanning at least 14 days with percentage change within +/-20% from the cut-off concentrations (SAI-Global, 2019). In addition, we report a variation trend with cocaine and benzoylecgonine at elevated temperatures, suggesting hydrolytic decomposition of cocaine and a concomitant increase in benzoylecgonine quantitative values. We confirm the cross-talk by showing that the percentage change in the profile of average cocaine-benzoylecgonine measurement is within the acceptance concentration range of +/-20%. This finding highlights the importance of precaution during storage and careful considerations during subsequent interpretation of liquid chromatography-mass spectrometry (LCMS) measurements. CI - Copyright (c) 2021 Riggio, Dave, Koscak, Blakey and Appleton. FAU - Riggio, Michela AU - Riggio M AD - Central Laboratories, Toxicology, Biochemistry Queensland Medical Laboratory (QML) Pathology, Brisbane, QLD, Australia. FAU - Dave, Keyur A AU - Dave KA AD - Central Laboratories, Toxicology, Biochemistry Queensland Medical Laboratory (QML) Pathology, Brisbane, QLD, Australia. FAU - Koscak, Branko AU - Koscak B AD - Central Laboratories, Toxicology, Biochemistry Queensland Medical Laboratory (QML) Pathology, Brisbane, QLD, Australia. FAU - Blakey, Mark AU - Blakey M AD - Central Laboratories, Toxicology, Biochemistry Queensland Medical Laboratory (QML) Pathology, Brisbane, QLD, Australia. FAU - Appleton, Charles AU - Appleton C AD - Central Laboratories, Toxicology, Biochemistry Queensland Medical Laboratory (QML) Pathology, Brisbane, QLD, Australia. LA - eng PT - Journal Article DEP - 20210705 PL - Switzerland TA - Front Toxicol JT - Frontiers in toxicology JID - 101777990 PMC - PMC8915805 OTO - NOTNLM OT - collection device OT - drugs of abuse OT - mass spectrometry OT - oral fluid OT - quantisal COIS- The authors were employed by company Queensland Medical Laboratory (QML) Pathology, under the Healius Pathology Pty Ltd network. QML Pathology has a commercial supplier/customer relationship with Abbott Diagnostics for supply of laboratory reagents, analysers, etc as the laboratory does with many other suppliers. Abbott Diagnostics assisted by providing collection and transportation devices and by recompensing the laboratory for cost of consumables required to perform the validation. This had no influence on the performance of the investigation or the conclusions reached. EDAT- 2022/03/18 06:00 MHDA- 2022/03/18 06:01 PMCR- 2021/07/05 CRDT- 2022/03/17 05:05 PHST- 2021/02/22 00:00 [received] PHST- 2021/05/31 00:00 [accepted] PHST- 2022/03/17 05:05 [entrez] PHST- 2022/03/18 06:00 [pubmed] PHST- 2022/03/18 06:01 [medline] PHST- 2021/07/05 00:00 [pmc-release] AID - 10.3389/ftox.2021.670656 [doi] PST - epublish SO - Front Toxicol. 2021 Jul 5;3:670656. doi: 10.3389/ftox.2021.670656. eCollection 2021.